PharmaNet’s General Medicine and Cardiovascular team offers experience in all stages of program design and development from Phase I QT/QTc testing through Phase IV registries. Our General Medicine and Cardiovascular team offers a complete range of services, with all services available on a stand-alone basis or as part of a comprehensive drug development program.
The General Medicine and Cardiovascular team conducts high quality, thorough QT/QTc studies at the clinical facilities of Anapharm, our early phase subsidiary. The Montréal, Canada clinic comprises 150 beds in four clinical units, which can be combined to accommodate large cohorts. Our Montréal facility provides experienced medical staff, a network of cardiology-specialist nurses, and ECG Holter recording equipment with the ability to monitor 49 subjects simultaneously.
Click here to learn more about our QT/QTc capabilities.
For Phase II–IIIa studies, our General Medicine and Cardiovascular team offers:
 Cardiovascular-specialist clinicians and project managers worldwide |
|
 |
Dedicated, experienced staff at all levels, including clinical research associates, data management professionals, biostatisticians, and medical writers |
|
Established relationships with many of the world’s leading cardiovascular centers and specialists, enabling access to a large network of investigators and patient populations |
| Senior-management oversight of all projects |
|
|
A collaborative approach among team members and sponsor staff to share best practices and knowledge about the competitive landscape |
|
The global resources to conduct programs wherever patient populations, economic conditions, and regulatory environment are most favorable |
|
A dedicated global safety and pharmacovigilance team. Click here to learn more about our safety capabilities and services. |
In the wake of recent, high-profile withdrawals of cardiovascular drugs, there is growing demand for safety-related, Phase IV studies. Our General Medicine and Cardiovascular team offers extensive experience in Phase IIIb–IV trials, expanded access programs, and patient registries. Click here for more information about our Phase IV capabilities and services.
Thomas A. Feld Executive Director, Clinical Research Mr. Feld has more than 30 years of experience in clinical research, including service in academia, in the pharmaceutical industry, and in contract research. Before coming to PharmaNet, he was Director of Operations at Covance, and held positions as Manager of Clinical Research at both Immunomedics and Bristol-Meyers Squibb. During his career, Mr. Feld has managed clinical studies in all phases, and in a wide variety of therapeutic areas, including oncology, cardiology, pain management, AIDS, diagnostic-imaging drugs, biologic agents, infectious diseases, and neuroscience. |
William Thomas Garland, MD, FACC Executive Medical Director Dr. Garland has nearly 25 years of experience in both medicine and the contract research industry. At PharmaNet, he assists in the strategic planning, design, and medical monitoring of Phase II–IV clinical studies. Prior to PharmaNet, Dr. Garland served as medical director in a variety of research facilities including Radiant Research, Garland & Associates, Squibb Institute for Medical Research, and the Louisiana Cardiovascular Research Center. Dr. Garland is board certified in both internal medicine and cardiovascular disease, and is a Fellow in the American College of Cardiology. |
504 Carnegie Center, Princeton, NJ 08540